PO.CL05.01 · 临床研究

“保存与扩增”流程:通过实现种子细胞的长期冷冻保存来提高自体肿瘤浸润淋巴细胞疗法可及性的关键里程碑

The "Preservation & Expansion" process: A key milestone for enhancing accessibility of autologous tumor-infiltrating lymphocyte therapy by enabling long-term cryopreservation of seed cells

海报缩略图:“保存与扩增”流程:通过实现种子细胞的长期冷冻保存来提高自体肿瘤浸润淋巴细胞疗法可及性的关键里程碑
编号 3699 展板 1 时间 4/20 02:00–05:00 区域 Section 40 主讲 Zhou He
分会场 Adoptive Cell Therapy 1
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Zhou He, Xingming Ma, Feng Yin, Shanshan Liang, Wenjia Zhuang, Hui Yan, Huajun Jin

Shanghai Juncell Therapeutics Co., Ltd, Shanghai, China

摘要 Abstract

中文摘要
背景:肿瘤浸润淋巴细胞(TIL)疗法在晚期实体瘤中已显示出有前景的疗效。然而,其自体性质构成了重大局限,因为许多晚期疾病患者不适合反复进行肿瘤切除,从而丧失了潜在的治疗机会。为克服这一挑战,我们开发了一种“保存与扩增”策略,即从初始肿瘤组织生成TIL种子细胞并冷冻保存,在需要治疗时按需扩增为最终产品(FP)。 目的:本研究旨在验证从冷冻保存不同储存时长后的TIL种子细胞扩增FP的可行性。 方法:对肿瘤组织进行处理并初步培养以生成种子细胞。由肿瘤组织生成的种子细胞或立即扩增(G0),或冷冻保存3天(G3D)、1、2、3或6个月(G1M-G6M),或1年或2年(G1Y、G2Y)后再扩增。在种子、中间和FP阶段评估细胞活力。对种子细胞和FP均进行表型分析(CD3+、CD8+、CD4+、CD56+),同时对FP进行功能分析,包括IFN-gamma分泌及通过实时细胞分析(RTCA)评估的细胞毒性。 结果:来自不同肿瘤组织的细胞在解冻后活力在不同冷冻保存时长间相当,结果如下(%):G0:79.7±6.4;G3D:80.9±5.1;G1M:81.0±5.8;G2M:80.2±3.9;G3M:81.3±4.7;G6M:81.0±5.3;G1Y:80.4±5.6;G2Y:80.8±4.8。此外,在REP培养阶段的各时间点均未观察到细胞活力的显著差异。流式细胞术表型表征显示,冷冻保存不同时长的种子细胞及其相应的最终细胞产品之间具有相似的表型谱。此外,冷冻保存时长对最终产品的效应功能影响甚微,各组IFN-gamma分泌水平和细胞毒性活性均维持良好即为佐证。IFN-gamma分泌水平(ng/ml)为:G0:14.5±7.0;G3D:15.0±4.2;G1M:13.4±5.0;G2M:14.8±5.0;G3M:16.5±5.0;G6M:16.5±5.0;G1Y:16.9±5.0;G2Y:20.4±5.0。通过RTCA评估的细胞毒性(%)如下:G0:76.8±7.9;G3D:78.1±4.3;G1M:78.3±8.9;G2M:77.4±9.0;G3M:79.2±8.3;G6M:79.9±3.7;G1Y:77.2±8.7;G2Y:83.2±3.6。 结论:TIL种子细胞在长达两年的长期冷冻保存后,仍可有效扩增为具有一致活力、表型、细胞因子分泌及细胞毒性的功能性FP。这些结果验证了“保存与扩增”流程作为一种稳健且可行的方法,通过将肿瘤切除与治疗时机解耦,提高了自体TIL疗法的可及性和实用性。
查看英文原文 English abstract
Background: Tumor-infiltrating lymphocyte (TIL) therapy has shown promising efficacy in advanced solid tumors. However, its autologous nature poses a major limitation due to the ineligibility of many patients with advanced disease for repeated tumor resections, leading to a loss of potential treatment opportunities. To overcome this challenge, we developed a “Preservation & Expansion” strategy, in which TIL seed cells are generated from initial tumor tissue and cryopreserved for on-demand expansion into final products (FP) upon treatment need. Objective: This study aimed to validate the feasibility of expanding FPs from cryopreserved TIL seed cells after various storage durations. Methods: Tumor tissues were processed and initially cultured to generate seed cells. Seed cells generated from tumor tissues were either immediately expanded (G0) or cryopreserved for 3 days (G3D), 1, 2, 3, or 6 months (G1M-G6M), or 1 or 2 years (G1Y, G2Y) prior to expansion. Cell viability was assessed at the seed, intermediate, and FP stages. Phenotypic analysis (CD3+, CD8+, CD4+, CD56+) was performed on both seed cells and FPs, while functional analyses, including IFN-gamma secretion and cytotoxicity via real-time cell analysis (RTCA), were conducted on the FPs. Results: Viability of cells derived from various tumor tissues post-thaw was comparable across different cryopreservation durations, with the following results (%): G0: 79.7±6.4; G3D: 80.9±5.1; G1M: 81.0±5.8; G2M: 80.2±3.9; G3M: 81.3±4.7; G6M: 81.0±5.3; G1Y: 80.4±5.6; G2Y: 80.8±4.8. Moreover, no significant differences in cell viability were observed during the REP culture phase at various time points. Phenotypic characterization by flow cytometry revealed similar profiles among seed cells cryopreserved for different durations and their corresponding final cellular products. Furthermore, cryopreservation duration had minimal impact on the effector functions of the final products, as evidenced by well-maintained levels of IFN-gamma secretion and cytotoxic activity across all groups. IFN-gamma secretion levels (ng/ml) were: G0: 14.5±7.0; G3D: 15.0±4.2; G1M: 13.4±5.0; G2M: 14.8±5.0; G3M: 16.5±5.0; G6M: 16.5±5.0; G1Y: 16.9±5.0; G2Y: 20.4±5.0. Cytotoxicity assessed by RTCA (%) was as follows: G0: 76.8±7.9; G3D: 78.1±4.3; G1M: 78.3±8.9; G2M: 77.4±9.0; G3M: 79.2±8.3; G6M: 79.9±3.7; G1Y: 77.2±8.7; G2Y: 83.2±3.6. Conclusion: TIL seed cells can be effectively expanded into functional FPs with consistent viability, phenotype, cytokine secretion, and cytotoxicity after long-term cryopreservation up to two years. These results validate the "Preservation & Expansion" process as a robust and feasible approach to improve the accessibility and practicality of autologous TIL therapy by decoupling tumor resection from treatment timing.
利益披露 Disclosure
Z. He, Shanghai Juncell Therapeutics Co., Ltd Employment. X. Ma, Shanghai Juncell Therapeutics Co., Ltd Employment. F. Yin, Shanghai Juncell Therapeutics Co., Ltd Employment. S. Liang, Shanghai Juncell Therapeutics Co., Ltd Employment. W. Zhuang, Shanghai Juncell Therapeutics Co., Ltd Employment. H. Yan, Shanghai Juncell Therapeutics Co., Ltd Employment. H. Jin, Shanghai Juncell Therapeutics Co., Ltd Employment.

← 返回 AACR 2026 检索